No, he didn't remove any cap he delayed it.
Biden's White House chief of staff, Ronald Klain,
announced a regulatory freeze of “any new and pending rules” as Biden took office on Jan. 20. The freeze on the insulin and epinephrine rule is effective until March 22.
According
to Bloomberg Law, "A regulatory pause is a common tradition among incoming presidents to ensure that the unfinished policies from the prior administration align with the new one."
The National Association of Community Health Centers, among others, expressed support for the new administration's move, saying the Trump rule would not have lowered the cost of insulin and EpiPens for most Americans who use them, as advertised.
HHS finalized the rule in late December. But in publishing that
final rule, HHS acknowledged "the economic impact is expected to be minimal" since the vast majority of patients who get insulin from community health centers already get discounted medication. In some cases, those patients receive a one-month supply of insulin for just $7, according to the
report published in the Federal Register.
And the
National Association of Community Health Centers confirmed for VERIFY that its member health centers already pass along their deeply discounted drug prices to the low-income families they serve.
“Their whole mission for 55 years has been to provide low-cost prescriptions and services to low-income families,” said NACHC vice president of media relations Amy Simmons Farber, who also said community health centers opposed the Trump administration plan. “The executive order was a slap in the face because we were already a low-cost alternative to high prescription drug prices. The executive order just created massive red tape. It’s not a good rule.”
Some media, politicians and social media users are claiming President Joe Biden raised the cost of insulin during his first week in the Oval Office.
www.wthr.com